Potent, Versatile & Programmable
Measles simple RNA virus is evolved and adapted to selectively replicate in and destroy cancer cells. Measles virus is a POTENT, VERSATILE & PROGRAMMABLE modality for precision targeting of many cancer types.
Features of our Measles virus Platform
Oncolytic Measles technology is exclusively licensed by Vyriad. All children are vaccinated during childhood using a live, but weakened strain of measles virus. This measles strain has been further evolved and adapted to preferentially infect and destroy human cancer cells, and is now being developed by Vyriad as a safe, effective cancer therapy. Vyriad’s measles platform has been engineered to increase its potency and to track its spread in the body, and can be targeted with high precision to specific molecules on the cancer cell surface. Measles infected cancer cells fuse with neighboring cancer cells, creating “multi-cellular syncytia” which die a few days later. Because human exposure to measles vaccine is almost universal, Vyriad is using its oncolytic measles virus both as a local therapy to bring the immune system into the cancer, and as a systemic therapy delivered using cell carriers to protect it from the immune system, or in cancer patients who have lost their antimeasles antibodies.
BOOSTS ANTI-CANCER IMMUNITY